Nucleai: How Nucleai's spatial biology tech aims to accelerate drug development

Nucleai, founded in 2018 and based in Chicago and Tel Aviv, is pioneering new ground in spatial biology. Its AI-powered technology provides crucial context for tumor analysis, moving beyond traditional, static biopsy images to highlight cellular interactions that influence disease progression and treatment response. Innovation, in many cases, happens at the overlap of different domains,...The post How Nucleai's spatial biology tech aims to accelerate drug development appeared first on Drug Discovery and Development.